ARCHIVES

Phase II Elotuzumab Study Demonstrates 33 Months PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Baltimore Resigns as Rockefeller President; Perry Named Medical Director At Ellis Fischel

December 13, 1991

Clearinghouse Funds Two Carcinogens And A Threat To Humans

March 17, 1978

Working Group Beings AID-Related Lymphoma research

October 19, 1990

ODAC Prefers Three-Hour Taxol Infusion. Says Data Dosage Still Uncertain

October 1, 1993

Waldmann, Columbia, Netherland, Receive Bristol-Myers Awards

April 17, 1992

Cancer Mortality Increase Of 5.2% Now 28% Or Less

January 30, 1976